Seres Therapeutics Inc (NAS:MCRB)
$ 0.7589 -0.017 (-2.19%) Market Cap: 114.94 Mil Enterprise Value: 221.66 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 49/100

Seres Therapeutics Inc To Discuss Topline Results From The Phase 2b ECO-RESET Study Evaluating SER-287 In Patients With Mild-To-Moderate Ulcerative Colitis Call Transcript

Jul 22, 2021 / 12:30PM GMT
Release Date Price: $7.95 (-61.83%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Seres Therapeutics Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Dr. Carlo Tanzi of Investor Relations. Please go ahead, sir.

Carlo Tanzi
Seres Therapeutics, Inc. - VP of IR & Corporate Communications

Thank you, and good morning. A press release announcing top line results from the SER-287 Phase IIb clinical study in patients with mild to moderate ulcerative colitis became available at 7 a.m. Eastern Time this morning and can be found on the Investors & News section of the company's website.

I'd like to remind you that we'll be making forward-looking statements relating to the potential impact of microbiome therapeutics; the safety, efficacy, regulatory and clinical progress of our product candidates; plans, timing and potential impact of the release of additional preclinical and clinical data, including the SER-287

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot